Hunter Syndrome Treatment Market

Mar 2021| MRS127A| Market Research Studies

Report Highlights

The scope of this report covers the different types of Hunter Syndrome Treatment along with emerging therapies for the treatment of Hunter Syndrome Treatment. The report covers the market value for the historic year 2019, followed by the base year 2020, estimated year 2021 and forecast period from 2020 to 2026 for each treatment type, route of administration, end-user, and regional markets, and the estimated values are derived from the manufacturers’ total revenues.

The report also includes a discussion of the major players across each of the regional Hunter Syndrome Treatment markets; it explains the major market drivers of the Global Hunter Syndrome Treatment industry, current trends within the industry, major applications, and the regional dynamics of the Global Hunter Syndrome Treatment Market.

The report concludes with a special focus on the vendor landscape, which includes detailed profiles of the major vendors in the Global Hunter Syndrome Treatment Market. Recent mergers and acquisitions, new product development is also catered in this report.

Report Includes

  • 35 tables and 43 figures
  • An up-to-date analysis of the Global Hunter Syndrome Treatment Market.
  • Analyses of the global market trends, with data from 2019, 2020, estimates for 2021, and projections of compound annual growth rates (CAGRs) through 2026.
  • Estimation of market size and revenue forecast for Global Hunter Syndrome Treatment Market, and corresponding market share analysis by treatment type, route of administration, end-user, and region.
  • Highlights of emerging technology trends, gaps and opportunities in the market estimating current and future demand for Hunter Syndrome Treatment, identification of the companies that are best positioned to meet this demand.
  • In-depth information (facts and figures) concerning market drivers, restraints and other forces affecting the progress of this market.
  • Identification of promising new therapies, and products still in the development and testing stages, and their probability of successful commercial launch within the next five years
  • Impact of COVID-19 on the Hunter Syndrome Treatment Market as compared to overall global economy.
  • Insight into the growth development strategies of major Hunter Syndrome Treatment manufacturers and their key competitive landscape
  • Descriptive company profiles of the leading market participants, REGENXBIO Inc., Takeda Pharmaceutical Company Limited, Clinigen Group PLC, JCR Pharmaceuticals Co., Ltd., Sangamo Therapeutics, and others.

Summary

Hunter Syndrome commonly known as mucopolysaccharidosis type II (MPS II), is a rare genetic disorder. This disorder is usually caused due to an enzyme deficiency of iduronate-2-sulfatase which is responsible for the breakdown of sugar molecules in the body. In hunter syndrome, the body is not able to digest the sugar molecules and would in turn cause severe mental and physical disabilities. Hunter syndrome is usually caused by the inheritance of a defective X chromosome and due to this, this disorder is also termed as X-linked recessive disease. As of now, there is no permanent cure for this disease but there are two existing treatment which focused on delivering symptomatic relief to the patients. Enzyme replacement therapy and hematopoietic stem cell transplant are the two treatment therapies which are used for the management of impediments associated with the disease progression.

According to National MPS Society, the hunter syndrome affects 1 in 100,000 to 1 in 170,000 males. During the COVID-19 pandemic, there has been a decrease in the mortality rate of hunter syndrome which has further affected numerous manufacturers. Apart from this, several diagnostic therapies and pipeline procedures have been put on hold in order to speed up the treatment procedure for coronavirus. Creating awareness among the people about the disease and how to treat the disorder is likely to propel the global hunter syndrome treatment market growth. Increasing pipeline product approvals is further going to drive the market during the forecast period.

The Global Hunter Syndrome Treatment Market was valued at $913 million in 2020 and is expected to witness a steady growth at a CAGR of 6.84%.

  • Table 1 : Global Hunter Syndrome Treatment Market, Through 2026
  • Table 2 : Global Hunter Syndrome Market, by Treatment Type, Through 2026
  • Table 3 : Global Hunter Syndrome Market, by Route of Administration, Through 2026
  • Table 4 : Global Hunter Syndrome Market, by End-User, Through 2026
  • Table 5 : Global Hunter Syndrome Market, by Region, Through 2026
  • Table 6 : North America Hunter Syndrome Market, by Treatment Type, Through 2026
  • Table 7 : North America Hunter Syndrome Market, by Route of Administration, Through 2026
  • Table 8 : North America Hunter Syndrome Market, by End-User, Through 2026
  • Table 9 : North America Hunter Syndrome Market, by Country, Through 2026
  • Table 10 : Europe Hunter Syndrome Market, by Treatment Type, Through 2026
  • Table 11 : Europe Hunter Syndrome Market, by Route of Administration, Through 2026
  • Table 12 : Europe Hunter Syndrome Market, by End-User, Through 2026
  • Table 13 : Europe Hunter Syndrome Market, by Country, Through 2026
  • Table 14 : Asia-Pacific Hunter Syndrome Market, by Treatment Type, Through 2026
  • Table 15 : Asia-Pacific Hunter Syndrome Market, by Route of Administration, Through 2026
  • Table 16 : Asia-Pacific Hunter Syndrome Market, by End-User, Through 2026
  • Table 17 : Asia-Pacific Hunter Syndrome Market, by Country, Through 2026
  • Table 18 : South America Hunter Syndrome Market, by Treatment Type, Through 2026
  • Table 19 : South America Hunter Syndrome Market, by Route of Administration, Through 2026
  • Table 20 : South America Hunter Syndrome Market, by End-User, Through 2026
  • Table 21 : South America Hunter Syndrome Market, by Country, Through 2026
  • Table 22 : Middle East & Africa Hunter Syndrome Market, by Treatment Type, Through 2026
  • Table 23 : Middle East & Africa Hunter Syndrome Market, by Route of Administration, Through 2026
  • Table 24 : Middle East & Africa Hunter Syndrome Market, by End-User, Through 2026
  • Table 25 : Middle East & Africa Hunter Syndrome Market, by Country, Through 2026
  • Table 26 : REGENXBIO Inc.: Financial Performance, Through 2020
  • Table 27 : Takeda Pharmaceutical Company Limited: Financial Performance, Through 2020
  • Table 28 : Clinigen Group PLC: Financial Performance, Through 2020
  • Table 29 : JCR Pharmaceuticals Co., Ltd.: Financial Performance, Through 2020
  • Table 30 : Sangamo Therapeutics, Inc.: Financial Performance, Through 2020
  • Table 31 : Bioasis Technologies Inc.: Financial Performance, Through 2020
  • Table 32 : Esteve Pharmaceuticals SA: Financial Performance, Through 2020
  • Table 33 : Avrobio Inc.: Financial Performance, Through 2020
  • Table 34 : CANbridge Life Sciences, Ltd.: Financial Performance, Through 2020
  • Table 35 : BioMarin Pharmaceutical, Inc.: Financial Performance, Through 2020
  • Figure 1 : Global Hunter Syndrome Treatment Market
  • Figure 2 : Global Hunter Syndrome Market, by Value, 2019-2026
  • Figure 3 : Global Hunter Syndrome Market, by Value, by Treatment Type, 2019-2026
  • Figure 4 : Global Hunter Syndrome Market, by Value, by Route of Administration, 2019-2026
  • Figure 5 : Global Hunter Syndrome Market, by Value, by End-User, 2019-2026
  • Figure 6 : Global Hunter Syndrome Market, by Value, by Region, 2020
  • Figure 7 : Global Hunter Syndrome Market, by Value, by Company, 2020
  • Figure 8 : Global Hunter Syndrome Market, Product Map, 2020
  • Figure 9 : North America Hunter Syndrome Market, by Value, 2019-2026
  • Figure 10 : North America Hunter Syndrome Market, by Value, by Treatment Type, 2019-2026
  • Figure 11 : North America Hunter Syndrome Market, by Value, by Route of Administration, 2019-2026
  • Figure 12 : North America Hunter Syndrome Market, by Value, by End-User, 2019-2026
  • Figure 13 : North America Hunter Syndrome Market, by Value, by Country, 2020
  • Figure 14 : Europe Hunter Syndrome Market, by Value, 2019-2026
  • Figure 15 : Europe Hunter Syndrome Market, by Value, by Treatment Type, 2019-2026
  • Figure 16 : Europe Hunter Syndrome Market, by Value, by Route of Administration, 2019-2026
  • Figure 17 : Europe Hunter Syndrome Market, by Value, by End-User, 2019-2026
  • Figure 18 : Europe Hunter Syndrome Market, by Value, by Country, 2020
  • Figure 19 : Asia-Pacific Hunter Syndrome Market, by Value, 2019-2026
  • Figure 20 : Asia-Pacific Hunter Syndrome Market, by Value, by Treatment Type, 2019-2026
  • Figure 21 : Asia-Pacific Hunter Syndrome Market, by Value, by Route of Administration, 2019-2026
  • Figure 22 : Asia-Pacific Hunter Syndrome Market, by Value, by End-User, 2019-2026
  • Figure 23 : Asia-Pacific Hunter Syndrome Market, by Value, by Country, 2020
  • Figure 24 : South America Hunter Syndrome Market, by Value, 2019-2026
  • Figure 25 : South America Hunter Syndrome Market, by Value, by Treatment Type, 2019-2026
  • Figure 26 : South America Hunter Syndrome Market, by Value, by Route of Administration, 2019-2026
  • Figure 27 : South America Hunter Syndrome Market, by Value, by End-User, 2019-2026
  • Figure 28 : South America Hunter Syndrome Market, by Value, by Country, 2020
  • Figure 29 : Middle East & Africa Hunter Syndrome Market, by Value, 2019-2026
  • Figure 30 : Middle East & Africa Hunter Syndrome Market, by Value, by Treatment Type, 2019-2026
  • Figure 31 : Middle East & Africa Hunter Syndrome Market, by Value, by Route of Administration, 2019-2026
  • Figure 32 : Middle East & Africa Hunter Syndrome Market, by Value, by End-User, 2019-2026
  • Figure 33 : Middle East & Africa Hunter Syndrome Market, by Value, by Country, 2020
  • Figure 34 : REGENXBIO Inc.: Revenue Share, 2020
  • Figure 35 : Takeda Pharmaceutical Company Limited: Revenue Share, 2020
  • Figure 36 : Clinigen Group PLC: Revenue Share, 2020
  • Figure 37 : JCR Pharmaceuticals Co., Ltd.: Revenue Share, 2020
  • Figure 38 : Sangamo Therapeutics, Inc.: Revenue Share, 2020
  • Figure 39 : Bioasis Technologies Inc.: Revenue Share, 2020
  • Figure 40 : Esteve Pharmaceuticals SA: Revenue Share, 2020
  • Figure 41 : Avrobio Inc.: Revenue Share, 2020
  • Figure 42 : CANbridge Life Sciences, Ltd.: Revenue Share, 2020
  • Figure 43 : BioMarin Pharmaceutical, Inc.: Revenue Share, 2020

Market Research Studies is a North Carolina based, premier market research company. MRS brings over 50 years of market research publishing experience. Our reports cover a variety of industries such as Healthcare, Chemicals, Materials & Manufacturing, Research & Diagnostics, Environment & Sustainability, among others. Each year MRS releases hundreds of reports covering various topics. These reports are prepared by our in-house of team of Industry expert analysts. We strive to provide in-depth market analysis with accurate data to help our customers make informed decisions.

Why BCC Research?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
CUSTOM RESEARCH

Need a custom data table, graph or complete report? Tell us more.

Contact Us
Share This Report